Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity

Details for Australian Patent Application No. 2006249245 (hide)

Owner Dana-Farber Cancer Institute, Inc. Novartis AG

Inventors Manley, Paul William; Griffin, James Douglas

Agent Davies Collison Cave

Pub. Number AU-B-2006249245

Parent 2002357992

Filing date 7 December 2006

Wipo publication date 4 January 2007

Acceptance publication date 5 November 2009

International Classifications

C07D 498/22 (2006.01) Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms

A61K 31/155 (2006.01) - Amidines (), e.g. guanidine (HNC(NH)NH), isourea (HNC(OH)NH), isothiourea (HNC(SH)NH)

A61K 31/535 (2006.01) - having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

A61K 31/55 (2006.01) - having seven-membered rings, e.g. azelastine, pentylenetetrazole

A61K 31/553 (2006.01) - having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine

A61P 19/08 (2006.01) Drugs for skeletal disorders

A61P 35/02 (2006.01) Antineoplastic agents

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

Event Publications

21 December 2006 Complete Application Filed

4 January 2007 Application Open to Public Inspection

  Published as AU-B-2006249245

5 November 2009 Application Accepted

  Published as AU-B-2006249245

4 March 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006249246-Programmable mask for fabricating biomolecule array or polymer array, apparatus for fabricating biomolecule array or polymer array including the programmable mask, and method of fabricating biomolecule array or polymer array using the programmable mask

2006249244-84P2A9: A prostate and testis specific protein highly expressed in prostate cancer